Group 1 - The company, Tailong Pharmaceutical (600222), announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives on August 15 [1] - The newly formed tenth board of directors includes Chairman Wang Rongtao, Vice Chairman Li Jingliang, and other members such as Chen Siliang, Chen Jinge, Luo Jianchao, Chen Qi (independent director with accounting expertise), Liu Yumin (independent director), Fang Liang (independent director), and Chen Fengyun (employee representative director) [1]

Meeting Overview - The third extraordinary general meeting of shareholders was held on August 15, 2025, at the company's conference room in Zhengzhou [2] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, using a combination of on-site and online voting [2][3] - All resolutions passed during the meeting were in compliance with the Company Law and the company's articles of association [2][5] Resolutions Passed - The proposal to abolish the supervisory board and amend the articles of association was approved [3] - Amendments to the rules of procedure for shareholder meetings, board meetings, and independent director work systems were also approved [4] - The election of the tenth board of directors, including both non-independent and independent directors, was conducted [4] Board of Directors Composition - The tenth board of directors consists of Chairman Wang Rongtao, Vice Chairman Li Jingliang, and other members including independent directors and a worker representative [30][31] - The board's term is set for three years, starting from the date of approval by the shareholders' meeting [31] Management Appointments - Li Jingliang was appointed as the General Manager, with other key appointments including Su Fengshan as Executive Vice General Manager and Zhao Hailin as Financial Officer [34] - The board secretary is Li Nianyun, and the securities affairs representative is Wu Ting, with all appointments aligned with the board's term [34][35] Legal Compliance - The meeting and its resolutions were witnessed by Henan Qianwen Law Firm, confirming that all procedures adhered to relevant laws and regulations [5][30]

Core Viewpoint - TaiLong Pharmaceutical's stock price increased by 3.24% to 7.00 CNY, reflecting positive market sentiment and trading activity [1] Company Overview - TaiLong Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on three core business segments: drug formulations, traditional Chinese medicine pieces, and pharmaceutical research and development services [1] - The company was established in 1993 and became the first listed pharmaceutical company in Henan Province when it went public on the Shanghai Stock Exchange in 1999 [1] Recent Developments - On August 15, TaiLong Pharmaceutical announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives [1] - The company elected five non-independent directors and three independent directors, with Wang Rongtao being appointed as the chairman of the tenth board of directors [1] - Wang Rongtao has previously held positions as the secretary and chairman of Zhengzhou High-tech Construction Group Co., Ltd., and currently serves as a member of the party branch and vice chairman of Zhengzhou High-tech Science City Investment Development Group Co., Ltd. [1] Stock Performance - The stock opened at 6.73 CNY, reached a high of 7.20 CNY, and a low of 6.64 CNY during the trading session [1] - The trading volume was 548,988 hands, with a total transaction value of 381 million CNY [1]

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the cancellation of the supervisory board and amendments to related articles, during its third extraordinary general meeting of shareholders for 2025 [2] Group 1 - The company held its third extraordinary general meeting of shareholders on August 15 [2] - The meeting resulted in the approval of the proposal to cancel the supervisory board [2] - Amendments to related articles were also approved during the meeting [2]

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the election of the chairman of the board at the first meeting of its tenth board of directors [2] Group 1 - The company held its first meeting of the tenth board of directors on August 15 [2] - The board approved the proposal for the election of the chairman [2]

Group 1 - The company announced that it will hold a staff representative meeting on August 15, 2025 [1] - Chen Fengyun has been democratically elected as the employee representative director of the company's tenth board of directors [1]

Group 1 - The core point of the article is that Tai Long Pharmaceutical (SH 600222) held its first board meeting of the tenth session on August 15, 2025, to discuss the appointment of the board secretary and other documents [2] - For the year 2024, the revenue composition of Tai Long Pharmaceutical is as follows: 79.38% from pharmaceutical manufacturing, 13.65% from pharmaceutical research and development, 6.71% from pharmaceutical distribution, and 0.27% from other businesses [2]

Core Points - The board of directors of Henan Tailong Pharmaceutical Co., Ltd. held its first meeting of the tenth session on August 15, 2025, with all nine directors present [1][2][3] - The meeting approved the election of Wang Rongtao as the chairman of the board, with a unanimous vote of 9 in favor [1] - Li Jingliang was elected as the vice chairman of the board, also with a unanimous vote of 9 in favor [2] - The board established various specialized committees, including the Strategy and Development Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with all members elected unanimously [2] - Li Jingliang was appointed as the general manager of the company, with a unanimous vote of 9 in favor [3] - Su Fengshan was appointed as the executive vice general manager, and three others were appointed as vice general managers, all with unanimous approval [3] - Zhao Hailin was appointed as the financial officer, and Li Nianyun was appointed as the board secretary, both with unanimous votes [4] - Wu Ting was appointed as the securities affairs representative, also with unanimous approval [4]

河南仟问律师事务所关于河南太龙药业股份有限公司 2025 年第三次临时股东大会的法律意见书 仟问律师事务所 CHAINWINLAWFIRM 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 网址(URL)：http://www.chainwinlaw.com 电邮(E-mail):qwlss@126.com 仟见字【2025】371 号 关于河南太龙药业股份有限公司 致：河南太龙药业股份有限公司 河南仟问律师事务所（以下简称"本所"）接受河南太龙药业股份有限公司（以 下简称"公司"）的委托，委派本所律师出席公司 2025 年第三次临时股东大会（以 下简称"本次股东大会"），就本次股东大会的召集和召开程序，出席本次股东大 会人员的资格，审议事项及其表决程序等相关事宜出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件、 材料。公司保证其向本所提供的文件和材料是完整、真实和有效的，且一切足以 影响本法律意见书的事实、文件和材料均已向本所披露，无任何隐瞒、疏漏之处。 （以下简称"《公司法》"）、 有鉴于此，本所律师根据《中华人民共和国公司法》 《中华人民共和国证 ...

Meeting Overview - The shareholders' meeting of Henan Tailong Pharmaceutical Co., Ltd. was held on August 15, 2025, at the company's conference room in Zhengzhou High-tech Industrial Development Zone [1] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, utilizing a combination of on-site and online voting methods [1][3] - All procedures for convening and conducting the meeting complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions [3][4] Voting Results - Non-cumulative voting resolutions were all passed with significant support, including: - A total of 151,054,504 votes (98.4456%) in favor, 1,343,931 votes (0.8759%) against, and 1,041,100 votes (0.6785%) abstaining for the first resolution [1] - Similar high approval rates were observed for subsequent resolutions, with votes in favor consistently above 98% [1][2] - Cumulative voting for the election of directors also showed strong support, with 151,676,834 votes (98.8512%) in favor for the election of non-independent directors [2] Legal Compliance - The meeting's resolutions were confirmed to be legally valid, as they met the required thresholds for special and ordinary resolutions, with over two-thirds and half of the voting rights respectively [3][4] - Legal representatives confirmed that all aspects of the meeting adhered to relevant laws and regulations, ensuring the integrity of the proceedings [4]